GHENT, Belgium, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC.
FMR LLC has notified Ablynx that the shareholding in Ablynx held through financial instruments by FMR Co., Inc., a subsidiary of Fidelity Management & Research Company, which itself is a subsidiary of FMR LLC (the ultimate parent company), has exceeded the 3% threshold as of 10 November 2016.
According to the notification, FMR Co., Inc.'s holding of Ablynx shares and voting rights through financial instruments has increased to 1,888,006 shares, corresponding to 3.10% of the current 60,921,732 outstanding Ablynx shares (versus 1.92% in the previous notification on 3 October 2016).
FMR LLC (taking into account the holdings of its subsidiary undertakings) currently holds a total of 5,543,898 Ablynx shares, representing 9.10% of the current 60,921,732 outstanding Ablynx shares.
The notified details are presented below:
|Name||% of shares and voting rights||% of shares and voting rights held through financial instruments||Total of both|
|Shares||Voting rights||Shares||Voting rights||Shares||Voting rights|
Fidelity Management & Research Company
FMR Co., Inc.
FIAM Holdings Corp.
Fidelity Institutional Asset Management Trust Company
FIAM Holdings Corp.
The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote on behalf of all their securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
Last updated on: 21/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.